Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SL-279252 · 1 trial · 13 indications
Number of participants with treatment emergent adverse events
Number of participants with dose limiting toxicities (DLTs)
| Arm | Type | Description |
|---|---|---|
| SL-279252 | EXPERIMENTAL | Intravenous administration; Two possible dosing schedules for SL-279252 may be evaluated |
| Name | Type | Description |
|---|---|---|
| SL-279252 | DRUG | The investigational product (IP), SL-279252, is a first-in-class agonist redirected checkpoint (ARC) fusion protein (FP) consisting of the extracellular domains of human programmed cell death 1 (PD- 1) and OX40L, linked by a central Fc domain (PD1-Fc-OX40L). |
Inclusion Criteria: Participants are eligible to be included in the study only if all the following criteria apply. 1. Subject has voluntarily agreed to participate by giving written informed consent in accordance with ICH/GCP guidelines and applicable local regulations. 2. Subject has a histologi...
SL-279252 is an investigational small molecule immune checkpoint therapy being developed by Shattuck Labs, Inc. for advanced solid tumors and lymphomas. It was studied in a Phase 1 clinical trial that enrolled 49 participants with cancers including squamous cell carcinoma of the head and neck, melanoma, non-small cell lung cancer, and Hodgkin lymphoma.
SL-279252 was studied as a treatment for squamous cell carcinoma of the head and neck, along with other advanced solid tumors and lymphomas. It was evaluated in a single Phase 1 trial in adults with these cancers. The trial has been completed, and SL-279252 remains an investigational agent rather than an approved therapy.
SL-279252 targets PD1, an immune checkpoint protein. By binding PD1, the drug is designed to interfere with checkpoint signaling that tumors use to suppress immune responses. The molecule is described as a PD1-Fc-OX40L construct, combining PD1 targeting with an OX40L component in a single agent.
SL-279252 is being developed by Shattuck Labs, Inc., which trades under the ticker STTK. The company sponsored the Phase 1 study of the drug in advanced solid tumors and lymphomas. Shattuck Labs is the developer associated with this asset.
SL-279252 is in Phase 1 development. It has been evaluated in one completed Phase 1 trial, and no later-stage trials are recorded. The drug is investigational and has not been approved by the FDA for any indication.
SL-279252 was studied in the Phase 1 trial NCT03894618, titled SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas. The completed, uncontrolled study enrolled 49 adults across the United States, Belgium, Canada, and Spain, and included squamous cell carcinoma of the head and neck among its cancer types.